Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia;La farmacoterapia de la pulmonía nosocomial por Staphylococcus aureus resistente a meticilina

Annals of Pharmacotherapy

Volumn 46, Issue 12, 2012, Pages 1678-1687

  Segarra Newnham, Marisel ^a   Church, Timothy J ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b PGY1 Pharmacy Resident VAMC   (United States)

Author keywords

Linezolid; MRSA; Nosocomial pneumonia; Staphylococcus aureus; Vancomycin; Ventilator associated pneumonia

Indexed keywords

AZTREONAM; CEFTAROLINE; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; CREATINE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG PENETRATION; DRUG TISSUE LEVEL; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; KIDNEY DYSFUNCTION; MEDLINE; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; TREATMENT RESPONSE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; CROSS INFECTION; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; VANCOMYCIN;

EID: 84872226989     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R370     Document Type: Review

References (48)

1. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized controlled study. Clin Infect Dis 2012;54:621-9. doi: 10.1093/cid/cir895
2. Torres A. Antibiotic treatment against methicillin-resistant Staphylococcus aureus hospital and ventilator-acquired pneumonia: a step forward but the battle continues. Clin Infect Dis 2012;54:630-2. doi: 10.1093/cid/cir907
3. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171: 388-41.
4. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health-care associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32. doi: 10.1016/j.ajic.2008.03.002
5. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12. doi: 10.1086/318486
6. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid Nosocomial Pneumonia Study group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25: 980-92. doi: 10.1016/S0149-2918(03)80118-2
7. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97. doi: 10.1378/chest.124.5.1789
8. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-94. doi: 10.1007/s00134-003-2088-1
9. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:18-55. doi: 10.1093/cid/cir034
10. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161(3 pt 1):753-62.
11. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90. doi: 10.1086/340353
12. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51. doi: 10.1016/j.diagmicrobio.2010.05.012
13. Jung YJ, Koh Y, Hong SB, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010;38:175-80. doi: 10.1097/CCM.0b013e3181b9ecea
14. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011;52:31-40. doi: 10.1093/cid/ciq031
15. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun JS, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010;38:1802-8. doi: 10.1097/CCM.0b013e3181eb3b96
16. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia. A meta-analysis of randomized controlled trials. Chest 2011;139:1148-55. doi: 10.1378/chest.10-1556
17. Lamer C, deBeco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37: 281-6. doi: 10.1128/AAC.37.2.281
18. Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin 2010;26:571-88. doi: 10.1185/03007990903512057
19. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-402.
20. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus in-fections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44
21. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006;57:699-704. doi: 10.1093/jac/dkl030
22. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38:521-8. doi: 10.1086/381202
23. Rybak M, Lomaestro B, Rotschaffer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98. doi: 10.2146/ajhp080434
24. Chung J, Oh JM, Cho EM, et al. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients. Anaesth Intensive Care 2011;39:1030-7.
25. Jeffres MN, Isakow W, Dohert JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-55. doi: 10.1378/chest.130.4.947
26. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32:325-34. doi: 10.1093/jac/32.2.325. Erratum: J Antimicrob Chemother 1993;32:925. doi: 10.1093/jac/32.6.925-a
27. Hazlewood KA, Brouse SD, Pitcher WD et al. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010;123:182.e1-7. doi: 10.1016/j.amjmed.2009.05.031
28. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 2011;55:5475-9. doi: 10.1128/AAC.00168-11
29. Package insert. Zyvox (linezolid). New York, NY: Pfizer, Inc., March 2012.
30. Conte JE, Golden JA, Kipps J, Zirlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-80. doi: 10.1128/AAC.46.5.1475-1480.2002
31. Boselli E, Breilh D, Rimmelé T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator associated pneumonia. Crit Care Med 2005;33:1529-33. doi: 10.1097/01.CCM.0000168206.59873.80
32. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between superiority and non-inferiority. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003658.pdf (accessed 2012 Apr 17).
33. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007;27:1189-97. doi: 10.1592/phco.27.8.1189
34. FDA drug safety communications: serious CNS reactions possible when linezolid (Zyvox) is given to patients taking certain psychiatric medications. http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm (accessed 2012 Jul 31).
35. Quinn DK, Stern TA. Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry 2009;11:353-6. doi: 10.4088/PCC.09r00853
36. Stefani S, Bongiorno D, Mongelli G et al. Linezolid resistance in staphylococci. Pharmaceuticals 2010;3:1988-2006. doi: 10.3390/ph3071988
37. De Cock E, Krueger WA, Sorensen S, et al. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection 2009;37:123-32. doi: 10.1007/s15010-008-8046-7
38. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007;195:202-11. doi: 10.1086/510396
39. Dumitrescu O, Badiou C, Bes M, et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect 2008;14:384-8. doi: 10.1111/j.1469-0691.2007.01947.x
40. Deresinksi S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2009;49:1072-9. doi: 10.1086/605572
41. Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time kill curve methods. J Antimicrob Chemother 2003;51:857-64. doi: 10.1093/jac/dkg160
42. Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:418-20. doi: 10.1128/AAC.47.1.418-420.2003
43. Chiang FU, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:3002-4. doi: 10.1128/AAC.47.9.3002-3004.2003
44. Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy 2010;30: 375-89. doi: 10.1592/phco.30.4.375
45. Pichereau S, Moran JJ, Hayney MS, Shukla SK, Sakoulas G, Rose WE. Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells. J Antimicrob Chemother 2012;67:123-9. doi: 10.1093/jac/dkr417
46. Package insert. Cubicin (daptomycin). Lexington, MA: Cubist Pharmaceuticals, September 2003.
47. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52. doi: 10.1086/430352
48. American Society of Health-System Pharmacists. Telavancin injection. http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=887. Published November 13, 2012 (accessed 2012 Nov 29).